Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01613352
Other study ID # 329 / E6 / 07
Secondary ID
Status Completed
Phase N/A
First received June 5, 2012
Last updated June 5, 2012
Start date March 2008
Est. completion date April 2011

Study information

Verified date June 2012
Source Helsinki University Central Hospital
Contact n/a
Is FDA regulated No
Health authority Finland:Valvira
Study type Interventional

Clinical Trial Summary

The aim was to assess the patient compliance and medical and psychosocial effects of same day hospital discharge after breast conserving surgery and sentinel node biopsy only.


Description:

The patients with small breast tumours (<2 cm)and clinically node negative disease, were randomized to receive breast conserving surgery and sentinel node biopsy as ambulatory surgery or inpatient-surgery.Complication rate, patient satisfaction and psychosocial outcomes were compared. The psychosocial effects of the treatment mode on their spouses were recorded as well.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date April 2011
Est. primary completion date April 2011
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- Breast cancer < 2cm

- Clinically node negative

- ASA I-II

Exclusion Criteria:

- Axillary clearance performed

- ASA III-IV

- No adult companion at home

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research


Intervention

Other:
Ambulatory surgery
Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.

Locations

Country Name City State
Finland Helsinki University Central Hospital, Jorvi Hospital Espoo HUS

Sponsors (1)

Lead Sponsor Collaborator
Helsinki University Central Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Psychosocial wellfare Difference between the groups in questionnaire measuring anxiety and psychosocial wellfare First postoperative day No
Secondary Number of complications and return to hospital rate The difference in the number of complications or return to the hospital rate between the groups one week Yes
See also
  Status Clinical Trial Phase
Withdrawn NCT04538833 - GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel Phase 2
Completed NCT04436744 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) Phase 2
Completed NCT02187744 - A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) Phase 3
Terminated NCT01155063 - Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients N/A
Recruiting NCT03949634 - Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD) Phase 3
Active, not recruiting NCT05730647 - Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients
Terminated NCT01919229 - A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Phase 2
Active, not recruiting NCT04293393 - Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients Phase 2
Completed NCT00713141 - Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer N/A
Recruiting NCT06341894 - Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer Phase 2
Not yet recruiting NCT06404736 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer Phase 2
Not yet recruiting NCT06404463 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer Phase 2
Not yet recruiting NCT06435104 - Aromatherapy in the Treatment of Early Breast Cancer Phase 2
Recruiting NCT03520894 - Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer N/A
Completed NCT03786198 - Activity Program During Aromatase Inhibitor Therapy N/A
Completed NCT02738970 - A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC) Phase 1
Recruiting NCT01792726 - A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer. N/A
Completed NCT00323479 - Arthralgia During Anastrozole Therapy for Breast Cancer Phase 4
Completed NCT03493854 - A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Phase 3
Recruiting NCT04291378 - The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer N/A